REGENXBIO Inc.
NASDAQ:RGNXBiotechnology
+$0.16 today
- Market cap
- $480.05M
- Beta
- 1.03
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$5.53
Volume 0.70M
Average 1.24M
RGNX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
REGENXBIO Inc.NASDAQ: RGNX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $3.86M fell 2.5% year over year, in line with the -3.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.
Context
- Depreciation & amortization amounted to 9.2% of revenue in FY2025, down 10.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -2.5% holds above the trailing-twelve-month pace of -3.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 15.62M USD
- Year-over-year change
- -3.7%
- 4-year CAGR
- +13.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.62M | -3.7% |
| FY2024 | 2024-12-31 | 16.22M | -6.4% |
| FY2023 | 2023-12-31 | 17.32M | +34.2% |
| FY2022 | 2022-12-31 | 12.91M | +35.0% |
| FY2021 | 2021-12-31 | 9.56M | — |
Depreciation & Amortization vs competitors
How RGNX compares with its peers on the latest reported figures
- RGNX's LTM Mar 2026 depreciation & amortization of $15.52M is the 2nd largest of the 10 companies compared; the peer median is $4.14M.
- Its year-over-year change of -3.0% is the 6th highest of 10, against a peer median of -1.7%.
- Depreciation & amortization amounts to 17.7% of revenue for RGNX, versus a peer median of 21.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $28.32M | +126.8% | +13.8% | 35.5% | |
| LTM Mar 2026 | $15.52M | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $10.18M | +0.4% | +20.7% | — | |
| LTM Mar 2026 | $7.93M | +15.5% | +25.3% | 9.0% | |
| LTM Mar 2026 | $5.93M | -59.2% | +20.0% | 32.8% | |
| LTM Jun 2026 | $4.14M | +59.6% | -33.3% | 4.8% | |
| LTM Mar 2026 | $3.61M | -20.6% | -13.1% | 9.9% | |
| LTM Mar 2026 | $2.18M | -186.0% | — | — | |
| LTM Mar 2026 | $2.07M | -23.3% | +70.7% | 46.4% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.99M | -1.7% | -30.8% | — |
| Peer median (excluding RGNX) | $4.14M | -1.7% | +16.9% | 21.3% | |
Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 127.84M | (280.32M) | (263.49M) | (227.1M) | (193.88M) |
| Depreciation & Amortization | 9.56M | 12.91M | 17.32M | 16.22M | 15.62M |
| Deferred Income Tax | (1.92M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 38.81M | 40.79M | 40.27M | 38.46M | 34.56M |
| Change in Working Capital | 40.22M | 13.98M | (10.89M) | 5.53M | 11.78M |
| Accounts Receivables | 14.12M | 4.82M | 3.94M | 9.71M | (7.66M) |
| Inventory | 29.3M | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.3M) | 18.79M | (2.79M) | (292K) | (2.28M) |
| Other Working Capital | (899K) | (9.64M) | (12.03M) | (3.88M) | 21.73M |
| Other Non-Cash Items | 4.36M | 5.16M | (1.61M) | (6.23M) | 7.96M |
| Operating Cash Flow | 218.88M | (207.49M) | (218.41M) | (173.13M) | (123.96M) |
| Capital Expenditures | (84.18M) | (30.72M) | (9.96M) | (2.44M) | (2.41M) |
| Acquisitions (Net) | (4.99M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (498.14M) | (184.88M) | (86.56M) | (190.14M) | (332.63M) |
| Sales of Investments | 175.68M | 203.67M | 287.47M | 290.24M | 319.11M |
| Other Investing Activities | 4.99M | 0 | 0 | 5.78M | 62K |
| Investing Cash Flow | (406.64M) | (11.93M) | 190.94M | 103.45M | (15.87M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 218.21M | 1.74M | 6.7M | 131.07M | 1.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 1.19M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22.96M) | (30.58M) | (41.67M) | (39.58M) | 115.76M |
| Financing Cash Flow | 195.25M | (28.84M) | (34.97M) | 92.68M | 116.77M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.48M | (248.26M) | (62.43M) | 23M | (23.06M) |
| Free Cash Flow | 134.7M | (238.21M) | (228.37M) | (175.56M) | (126.38M) |
REGENXBIO Inc.
NASDAQ:RGNX
Intrinsic Alpha fair value
Locked
Current Price
$7.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.